Epidemiological and Economic Burden of Alzheimer's Disease: A Systematic Literature Review of Data across Europe and the United States of America

被引:167
作者
Takizawa, Claire [1 ]
Thompson, Paula L. [2 ]
van Walsem, Anneloes [3 ]
Faure, Celine [4 ]
Maier, William C. [2 ]
机构
[1] Nestle Hlth Sci, Vevey, Switzerland
[2] Mapi, London, England
[3] Mapi, Houten, Netherlands
[4] Mapi, Lyon, France
关键词
Alzheimer's disease; direct costs; economic; epidemiology; incidence; indirect costs; medical costs; mortality; non-medical; costs; prevalence; MILD COGNITIVE IMPAIRMENT; COST-EFFECTIVENESS; HEALTH-CARE; VASCULAR DEMENTIA; ELDERLY POPULATION; PREVALENCE; MORTALITY; DONEPEZIL; SPAIN; AGE;
D O I
10.3233/JAD-141134
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Alzheimer's disease (AD) weighs heavily on health expenditure and is strongly associated with increasing age. Due to population aging, increasing global prevalence of AD will pose huge challenges to public health and elderly care systems in all countries across the world. Objectives: This study aimed to better understand the burden of AD from a healthcare perspective. Methods: A systematic literature review of journal articles published between January 2002 and December 2012 was performed for studies conducted in France, Germany, Italy, The Netherlands, Spain, the United Kingdom (UK), and the United States of America (USA), using Medline, Embase, and the NHS Economic Evaluation Database. Results: 3,288 references were initially retrieved, and 39 epidemiological and 66 economic publications were selected for data extraction. AD incidence rates greatly varied between countries; however, prevalence was more consistent across all included countries, ranging between 3-7%. Overall, medical costs were lower in France compared to other included countries and increased with AD severity, e. g., direct medical costs per year for mild AD ranged from 5,476 int$ in France to 27,380 int$ in Spain. Limitations, such as heterogeneous methodology and missing data, prevented the comparison of results across studies between countries or the conclusion of any trend over time. Conclusion: This review corroborates previous understanding that AD burden is high for both society and healthcare providers. Limitations regarding study heterogeneity restricted conclusions; further research is required. Stakeholders could benefit from new healthcare strategies addressing both epidemiological and economic aspects of AD.
引用
收藏
页码:1271 / 1284
页数:14
相关论文
共 70 条
[1]   Age Patterns of Incidence of Geriatric Disease in the US Elderly Population: Medicare-Based Analysis [J].
Akushevich, Igor ;
Kravchenko, Julia ;
Ukraintseva, Svetlana ;
Arbeev, Konstantin ;
Yashin, Anatoliy I. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (02) :323-327
[3]   Prevalence of dementia and apolipoprotein E genotype distribution in the elderly of Buttapietra, Verona province, Italy [J].
Benedetti, MD ;
Salviati, A ;
Filipponi, S ;
Manfredi, M ;
De Togni, L ;
Lira, MG ;
Stenta, G ;
Fincati, E ;
Mampanin, M ;
Rizzuto, N ;
Danti, G .
NEUROEPIDEMIOLOGY, 2002, 21 (02) :74-80
[4]  
Bickel H, 2006, NERVENARZT, V77, P1079, DOI 10.1007/s00115-005-1949-y
[5]   National estimates of the prevalence of Alzheimer's disease in the United States [J].
Brookmeyer, Ron ;
Evans, Denis A. ;
Hebert, Liesi ;
Langa, Kenneth M. ;
Heeringa, Steven G. ;
Plassman, Brenda L. ;
Kukull, Walter A. .
ALZHEIMERS & DEMENTIA, 2011, 7 (01) :61-73
[6]  
Bufill E, 2009, NEUROLOGIA, V24, P102
[7]   Clinical and demographic characteristics of the cases of dementia diagnosed in the Health District of Girona throughout the period 2007-2010: data from the Girona Dementia Registry (ReDeGi) [J].
Calvo-Perxas, Laia ;
Teresa Osuna, M. ;
Gich, Jordi ;
Eligio-Hernandez, Erelido ;
Linares, Marta ;
Vinas, Marta ;
Casas, Isabel ;
Turro-Garriga, Oriol ;
Lopez-Pousa, Secundino ;
Garre-Olmo, Josep .
REVISTA DE NEUROLOGIA, 2012, 54 (07) :399-406
[8]   Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries [J].
Caro, J ;
Salas, M ;
Ward, A ;
Getsios, D ;
Migliaccio-Walle, K ;
Garfield, F .
DRUGS & AGING, 2004, 21 (10) :677-686
[9]   Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands [J].
Caro, JJ ;
Salas, M ;
Ward, A ;
Getsios, D ;
Mehnert, A .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2002, 14 (02) :84-89
[10]   Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer's Disease Type in Spain: The ECO Study [J].
Coduras, Alicia ;
Rabasaa, Isabel ;
Frank, Ana ;
Bermejo-Pareja, Felix ;
Lopez-Pousa, Secundino ;
Lopez-Arrieta, Jesus-Maria ;
Del Llano, Juan ;
Leon, Teresa ;
Rejas, Javier .
JOURNAL OF ALZHEIMERS DISEASE, 2010, 19 (02) :601-615